The transition from preclinical research to human trials requires strict adherence to regulatory standards to protect human subjects and ensure the scientific validity of the proposed research. Before any clinical trial can commence, sponsors must compile an extensive dossier of non-clinical data, manufacturing information, and clinical plans to request authorization from the NMPA. A poorly prepared submission package can result in clinical holds, requests for supplementary information, or outright rejection, thereby delaying drug development programs.
A third-party pre-submission audit serves as an objective, independent quality control mechanism. At Protheragen, we combine deep regulatory knowledge with hands-on auditing experience to deliver thorough, objective pre-submission audit services. Our audit is designed to provide sponsors with a clear picture of their submission's strengths and areas that require attention before official filing.
During this audit, our team of regulatory and scientific auditors meticulously reviews the submission package against current NMPA regulations, guidelines issued by the Center for Drug Evaluation (CDE), and relevant International Council for Harmonisation (ICH) standards. The primary objective is to verify the internal consistency, scientific rationale, and regulatory alignment of the application.
We review the non-clinical study reports to verify that appropriate animal models were used, Good Laboratory Practice (GLP) standards were maintained, and the toxicological profile supports the proposed starting dose in humans. We check for clear articulation of the safety margins and risk mitigation strategies.
Our auditors examine the CMC data for the active pharmaceutical ingredient (API) and the investigational medicinal product (IMP). This includes a review of the manufacturing process, impurity profiles, stability data, and analytical validation to ensure phase-appropriate quality control.
We assess the clinical study protocol for scientific soundness and regulatory compliance. This includes an evaluation of the study objectives, primary and secondary endpoints, inclusion and exclusion criteria, statistical methodology, and patient safety monitoring plans.
The IB is audited to ensure it accurately synthesizes all available non-clinical and CMC data. We verify that the IB provides clinical investigators with a clear, objective understanding of the investigational product's potential risks and expected pharmacological effects.
We review the draft ICF and other patient-facing materials to verify that they accurately reflect the risks outlined in the protocol and the IB, are written in comprehensible language, and comply with ethical standards and GCP requirements.
We conduct a structural and formatting review of the administrative modules, ensuring that all documentation aligns structurally and factually with NMPA regulatory requirements to prevent avoidable delays during the initial preliminary review.
Engaging an independent third-party auditor brings an objective perspective to the submission preparation process. Internal teams, however experienced, may develop blind spots after extended periods working with the same documents. A fresh, external review can identify inconsistencies, gaps in cross-referencing, formatting issues, and subtle deviations from regulatory expectations that might otherwise go unnoticed. Furthermore, NMPA guidelines continue to evolve, and a specialized auditor stays current with the latest regulatory trends, technical guidance documents, and common deficiency patterns observed in recent NMPA reviews. This external perspective complements the work of the sponsor's own regulatory affairs team and contributes to a more robust, defensible submission package.
To learn more about our pre-submission audit service for clinical trial applications to the NMPA, or to discuss your specific needs with our audit team, please contact us. We are available to provide further information and answer any questions you may have.
1. How does a pre-submission audit differ from an NMPA regulatory inspection?
A pre-submission audit is a voluntary, sponsor-commissioned review conducted by an independent third party before filing. An NMPA regulatory inspection, in contrast, is an official government-led examination that occurs after submission. The pre-submission audit is proactive and confidential, intended to prepare the sponsor for the formal regulatory process.
2. What happens to the audit findings after the report is delivered?
The primary deliverable is a detailed audit report that categorizes findings and provides recommendations. Following the report, sponsors may request a follow-up review of the remediation actions. This is an optional step in which the auditor re-examines the updated sections to verify that the identified findings have been satisfactorily addressed before the NMPA submission.
3. Does this audit service include rewriting or editing the clinical trial application documents?
No. To maintain strict objectivity as a third-party auditor, our role is to evaluate the documentation for regulatory compliance and scientific integrity. We provide a detailed report outlining identified gaps and specific recommendations, but the actual revision or medical writing of the documents remains the responsibility of the sponsor.
4. What type of expertise do the auditors performing this pre-submission review possess?
The review is conducted by a multidisciplinary team of subject-matter experts. This includes regulatory affairs specialists, pharmacologists, toxicologists, and Chemistry, Manufacturing, and Controls (CMC) professionals who possess in-depth knowledge of current NMPA/CDE regulations and international drug development standards.